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ABSTRACT
The anticonvulsant activity of bis(acetato)tetrakis(imidazole) cop-
per(II), Cu(OAc)2(Im)4, was studied in normal mice using chemical con-
vulsions induced by strychnine, thiosemicarbazide, picrotoxin, and
pentelenetetrazol. Intraperitoneal administration of Cu(OAc)2(Im)4, 50
mg/kg body mass, has delayed the onset of strychnine (3 mg/kg)-induced
convulsion by 204% (p ≤ 0.005) and thiosemicarbazide (20 mg/kg)-induced
convulsant by 61% (p ≤ 0.005). The changes in the onset of picrotoxin- (6
mg/kg) and pentelenetetrazol (50 mg/kg)-induced convulsions were not
significant. The same dosage of the copper compound was effective in
delaying the lethal time and reducing the mortality rate of treated animals.
The anticonvulsant activity of Cu(OAc)2(Im)4 complex against strychnine
was not related to its constituents because the inorganic form of copper
such as copper chloride, copper acetate, and the parent imidazole has no
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anticonvulsant activity. Other copper(II) complexes like copper(II)aspiri-
nate and bis(acetato)bis(2-methyl imidazole) copper(II) were less effective.
Index Entries: Copper(II) acetate–imidazole; strychnine; anticonvul-
sants; thiosemicarbazide; picrotoxin; pentylenetetrazol; onset of convulsion.
INTRODUCTION
Copper is recognized as an essential metalloelement, which is
required for normal metabolic processes. Many of the key enzymes such as
hemocyanin cytochrome oxidase, superoxide dismutase, tyrosinase,
dopamine-β-hydroxylase, and amine oxidases are copper-dependent
enzymes (1–3). The pharmacological activities of copper complexes are
consistent with the putative role of Cu-Zn superoxide dismutase and other
copper oxidase metalloenzymes in the prevention of tissue damage (4).
Copper complexes have been shown to have many pharmacological
activities such as anti-inflammatory (5–8), antiulcer (9), antitumor (2,10,11),
antidiabetic (2,12,13), radio-protectant (14–16), as well as anticonvulsant
activity (10,12,17,18). In many cases, the copper complex of some
antiepileptic drugs has been shown to be more effective than their parent
ligand (19,20). The hypothesis that seizures results from an inadequate sup-
ply of copper and loss of copper-dependent enzyme activity is consistent
with the high-affinity transport of copper through the brain–blood barrier
(21) and the fact that postmortem samples of brain tissue from epileptic
patients have a very low copper concentration (22). Seizures as well as cere-
bral degeneration occur in copper-deficient animals (23,24), and chelating
agents that produce tremors in animals also reduce brain copper levels (25).
The present study was undertaken to investigate the protective effect
of some copper complexes on chemical convulsions induced by strych-
nine, thiosemicarbazide, picrotoxin, and pentylenetetrazol.
MATERIALS AND METHODS
Reagents and Materials
Strychnine, picrotoxin, thiosemicarbazide, and pentylenetetrazol
were purchased from Sigma Chemicals Co. (St. Louis MO). Copper(II)
chloride and imidazole were purchased from Aldrich (Milwaukee, WI).
Copper(II) acetate complexes were synthesized and characterized as pre-
viously described (26,27).
Animals and Administration of Drugs
White female mice weighing approx 30 g were used throughout the
experiments. Chemical convulsions were induced by intraperitoneal
injection of strychnine (3 mg/kg), thiosemicarbazide (20 mg/kg), picro-
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toxin (6 mg/kg), and pentylenetetrazol (50 mg/kg) and the animals were
kept under constant observation for measuring the behavioral changes,
onset of seizure, lethal time, and the mortality incidence recorded after a
24-h period. Treated animals were injected intraperitoneally (ip) for 30
min with 50 mg/kg body mass of the following compounds:
Cu(OAc)2(Im)4, Cu(II)asparinate, or a vehicle containing imidazole, cop-
per(II)2(acetate)4, or copper(II)chloride. Control animals were pretreated
for the same period with saline (0.9% [w/v] NaCl).
Values were expressed as mean values ± standard error of the mean
for the number of experiments indicated in parentheses, and the Student’s
t-test was used for all statistical analyses.
RESULTS AND DISCUSSION
Chemical Convulsions
Table 1 shows that intraperitoneal injection of mice with strychnine (3
mg/kg) produced convulsions after a latent period of 4.65 ± 0.56 (8) min,
thiosemicarbazide (20 mg/kg) produced convulsions after 52.83 ± 0.98 (6)
min, picrotoxin (6 mg/kg) produced clonic convulsions after 11.57 ± 0.98
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Table 1
Effect of Cu(OAc)2(Im)4 (50 mg/kg) on the Onset of Convulsions
Induced by Strychnine, Thiosemicarbazide, Picrotoxin, 
and Pentylenetetrazol
Note: Mice were injected intraperitoneally with strychnine (3 mg/kg), thiosemi-
carbazide (20 mg/kg), picrotoxin (6 mg/kg), or pentylenetetrazol (50 mg/kg) and the
onset of convulsions was recorded. Treated animals were injected with Cu(OAc)2(Im)4
(50 mg/kg [ip]) for 30 min before injection of the convulsants. Control animals were
injected intraperitoneally for the same period with the same volume of saline. Anti-
convulsant activity is the percentage change at the onset of convulsion between treated
and control animals. Values are mean ± SEM for the number of animals indicated in
parentheses. NS = nonsignificant.
(5) min, and pentylenetetrazol (metrazol) (50 mg/kg) produced clonic
tonic convulsions after 3.36 ± 0.44 (6) min.
In this experiments, we used minimal doses to induce chemical
seizures, and the convulsants are well known for their effect on GABA and
glutamate neurotransmission. Strychnine blocks inhibition mediated by
glycine (28), thiosemicarbazide inhibits GAD activity by an action on its
coenzyme pyridoxal phosphate (29), and picrotoxin acts by blocking the
inhibitory synaptic action of GABA (30). Pentylenetetrazol (metrazol) is
well known to be a general excitant in the central nervous system (31).
From our results, it is clear that strychnine is the most potent convulsant,
because an intraperitoneal injection of a small dosage (3 mg/kg) was
enough to induce convulsions after 4.65 ± 0.56 (8) min and death after 6.37
± 0.54 (8), with a mortality rate of 100% (see Table 2)
Anticonvulsant Activity of Copper(II)acetate–Imidazole
The synthesis and spectroscopic and X-ray structural characterization
of the copper(II)acetate–imidazole complex, Cu(OAc)2(Im)4, was previ-
ously reported by one of our colleagues (27). It was prepared by the reac-
tion of excess imidazole with Cu2(OAc)4. Its spectral parameters are
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Table 2
Effect of Bis(acetato)tetrakis(imidazole) Copper(II) on the Onset of Convulsions,
Death, and Mortality Rate of Mice Treated with Strychnine and Thiosemicarbazide
Note: Mice were injected intraperitoneally with strychnine (3 mg/kg) or thiosemicarbazide
(20 mg/kg); the onset of convulsions, lethal time, and mortality rate was recorded. Other ani-
mals from the same batch were pretreated for 30 min with Cu(OAc)2(Im)4 (50 mg/kg [ip]) before
injection of the convulsants. Values are mean ± SEM. for the number of animals indicated in
parentheses.
characteristic of a tetragonally elongated monomeric copper(II) complex
having a CuN4 … O2 chromophore that was verified by single-crystal X-
ray structural analysis (27). The structure of the complex is shown in Fig.
1. The Cu ion resides in a distorted octahedral environment that consists
of four coordinated imidazole nitrogen atoms in a plane with two weak
interacting carboxylate oxygen atoms in a plane disposition along a vector
that is nearly perpendicular to the plane of the imidazole nitrogen atoms
(see Fig. 1) (27). The complex is blue violet, very stable at room tempera-
ture and at atmospheric air, and is soluble in most organic solvents (alco-
hols, dimethylsulfoxide [DMSO], acetonitrile, etc.).
Copper(II)acetate–imidazole, Cu(OAc)2(Im)4 (50 mg/kg), injected
intraperitoneally for 30 min before treatment with the convulsants, delayed
the onset of strychnine convulsion by 204% (p < 0.005) and the onset of
thiosemicarbazide by 65% (p < 0.0005). The same copper complex has
increased the onset of picrotoxin- and metrazol-induced convulsions by 30%
and 38%, respectively, but the effect was not significant (see Tables 1 and 2).
Pretreatment with the copper complex Cu(OAc)2(Im)4 delayed the
onset of strychnine convulsion by 204% and the time to death by 169% and
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Fig. 1. Oak Ridge Thermal Ellipsoid Plot (ORTEP) drawing of
Cu(C3H4N2)4(O2CCH3)2 showing 50% probability of thermal ellipsoids.
reduced the mortality rate by 20%. With thiosemicarbazide, the copper
complex delayed the onset of convulsion by 65% and the time to death by
115% and reduced the mortality rate by 35%. The same copper complex
was found previously to have an antidiabetic activity (13), which indicates
the general protective mode of copper complexes in repairing of tissue
injury that occur in many of these diseases (2,18).
In previous reports, all of the metal complexes of 3,5-diisopropylsalicy-
late (DIPS), including copper, iron, and zinc, were found to have anticonvul-
sant activities, by preventing metrazol and maximal electroshock-induced
seizures (15,32). The anticonvulsant activity of Cu(II)2(3,5-DIPS)4 was related
to the decrease in nitric oxide synthesis in animal models of epilepsy.
Anticonvulsant Activities of Other Copper Complexes 
and Ligands
Figure 2 shows that copper acetate imidazole, Cu(OAc)2(Im)4 was the
most effective copper complex when tested against strychnine induced
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Fig. 2. The anticonvulsant activity of copper compounds was tested by meas-
uring the onset of strychnine convulsion following pretreatment with different
copper complexes and inorganic compounds: copper acetate imidazole (CAI),
copper asparinate, copper acetate 2-methyl imidazole (2-methyl CAI), copper
acetate, imidazole, and saline. All of these compounds were injected (ip) 30 min
before injection of strychnine (3 mg/kg).
seizures. It has delayed the onset of strychnine convulsions by 256% (p
<0.0005). Copper asparinate has delayed the onset of convulsions by 159%
(p < 0.005) and copper acetate-2-methylimidazole by 57% (p < 0.05). Pre-
treatment with saline, imidazole or copper acetate have no effect on the
onset of strychnine induced seizures.
The dimethyl (DMF) and diethylether ternary complexes of
Cu(II)2(3,5-DIPS)4 were found to have anticonvulsant activity in the maxi-
mal electroshock model of grand mal epilepsy, and Cu(II)2(3,5-
DIPS)4(DMF)2 was also effective against the metrazol model of seizure
(33). Binuclear and mononuclear 1,10-phenanthroline and salicylate ter-
nary copper(II) complexes were effective in preventing MES-induced
seizures and ineffective in preventing metrazol-induced seizures (20).
Cu(II)2(aspirinate)4(DMF)2 was an effective anticonvulsant in the MES
model of seizure, but ineffective against metrazol-induced seizures (34).
In vitro, it was reported that copper can modulate glutamate, GABA,
and glycine receptors, spontaneous glutamate-mediated excitatory synap-
tosomal activity was completely blocked by copper (35), and copper could
have a presynaptic effect on transmitter release via inhibition of voltage-
gated calcium channels.
It has been suggested that copper(II) complexes of anti-inflammatory
and anticonvulsant drugs are often more active, less toxic, and desirable
drugs than the parent ligand themselves (20,36,37). It seems that copper
complexes increase the bioavailability of copper and the activation of cop-
per-dependent enzymes, which are essential for normal physiological
processes and prevention of tissue damage. Copper complexes have super-
oxide dismutase mimetic activity that prevents tissue damage by dismuta-
tion of free active radicals such as superoxide and hydroxyl radicals (12).
In conclusion, the results reported here add further evidence to the
copper complexes, which can play a part in inhibition of chemically
induced seizures in addition to there antidiabetic and anti-inflammatory
activity. Copper(II)–imidazol complexes can provide protection against
seizures induced by strychnine and thiosemicarbazide without a having
significant effect on picrotoxin- and pentylenetetrazol-induced convul-
sions. Further experiments are needed to elucidate the mechanism of
action of the copper(II)acetate–imidazole complexes.
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